AKBA On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
akebia therapeutics inc
Akebia Therapeutics, Inc. Announces Resignation of Scott A. Canute as Class I Director

On June 10, 2019, Scott A. Canute, a Class I Director, notified Akebia Therapeutics, Inc. of his intention to resign from the company’s Board of Directors for personal reasons, effective as of June 10, 2019. The company and Mr. Canute entered into a consulting agreement, effective as of June 10, 2019, pursuant to which Mr. Canute will provide certain consulting services to the company.

Akebia Therapeutics, Inc. Launches AkebiaCares, an Enhanced Patient Access Program for People with Chronic Kidney Disease

Akebia Therapeutics, Inc. announced the launch of AkebiaCares, its enhanced patient access program. AkebiaCares provides patients, caregivers and health care providers with resources and important information to support greater access to Auryxia (ferric citrate). Auryxia is the only oral iron tablet approved in the U.S. to treat non-dialysis-dependent-chronic kidney disease (CKD) adult patients for iron deficiency anemia (IDA), and dialysis-dependent CKD adult patients for hyperphosphatemia. AkebiaCares offers services that include assisting patients and health care providers through the benefits investigation process, prior authorizations, appeals, copay assistance, and a patient assistance program for financially eligible patients. Patients can access these programs at www.akebiacares.com.

Akebia Therapeutics, Inc. Presents at Jefferies 2019 Healthcare Conference, Jun-04-2019 03:00 PM

Akebia Therapeutics, Inc. Presents at Jefferies 2019 Healthcare Conference, Jun-04-2019 03:00 PM. Venue: Grand Hyatt, 109 E 42nd St, New York, New York, United States. Speakers: John P. Butler, CEO, President & Director.

Akebia Therapeutics, Inc. Presents at Raymond James Life Sciences and MedTech Conference, Jun-19-2019 10:55 AM

Akebia Therapeutics, Inc. Presents at Raymond James Life Sciences and MedTech Conference, Jun-19-2019 10:55 AM. Venue: Lotte New York Palace hotel, New York, New York, United States. Speakers: John P. Butler, CEO, President & Director.

Akebia Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2019; Announces Full Enrollment of its Global Phase 3 INNO VATE Studies for Vadadustat

Akebia Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2019. For the quarter, the company reported collaboration revenue of $72,666,000 against $45,930,000 a year ago. Operating loss was $75,969,000 against $24,498,000 a year ago. Net loss was $72,421,000 against $23,418,000 a year ago. Net loss per basic and diluted share was $0.62 against $0.48 a year ago. The company announced full enrollment of its global Phase 3 INNO VATE studies for vadadustat, that it has bolstered its commercial capabilities with the addition of Dell Faulkingham as Senior Vice President, Chief Commercial Officer, and appointed Steven K. Burke, M.D., as Senior Vice President, Chief Medical Officer. Dr. Burke will join the company from Proteon Therapeutics, Inc., where he has been Senior Vice President and Chief Medical Officer since 2006. The first quarter marked the achievement of another important milestone for Akebia with the announcement of positive top-line results from two Phase 3, active-controlled, pivotal studies evaluating vadadustat in Japanese patients with anemia due to chronic kidney disease (CKD), stated John P. Butler, President and Chief Executive Officer of Akebia Therapeutics. The company also announced the completion of enrollment in global Phase 3 INNO 2VATE studies evaluating vadadustat for the treatment of anemia due to CKD in dialysis-dependent CKD subjects. With the addition of Dell Faulkingham to executive team, and have strengthened the commercial capabilities and believe that well positioned to execute on revenue growth strategies for Auryxia.

\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

AKBA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AKBA.
View Industry Companies
 

Industry Analysis

AKBA

Industry Average

Valuation AKBA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact AKEBIA THERAPEUTICS INC, please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.